Why Is Anti-Cancer Focused Aadi Bioscience Stock Trading Lower Today?

Zinger Key Points
  • 80 patients are enrolled in PRECISION1 supporting two-thirds interim analysis expected in 3Q 2024, data readout expected in early 2025.
  • Preliminary data from pre-planned analysis show clinical benefit in pretreated cancer patients.

Aadi Bioscience Inc AADI shares are trading lower after the company released results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial of nab-sirolimus in patients with TSC1 or TSC2 inactivating alterations

The interim analysis includes data from the first third of trial participants (n=40) with a minimum of 4.5 months of follow-up, including investigator-assessed response and safety analyzed separately in each TSC1 and TSC2 arms. 

Efficacy of nab-sirolimus in patients with tumors harboring pathogenic inactivating alteration in TSC1

  • A 26% Overall Response Rate (ORR), including five partial responses (PR) with four confirmed responses and one unconfirmed response (uPR).
  • All responses were ongoing at the time of data cutoff. The patient with uPR remains on treatment and is awaiting a confirmatory scan.
  • Nine patients had stable disease (SD), 3 of which were greater than or equal to six months in duration, resulting in a clinical benefit rate of 42%.
  • 60% of responders experienced > 50% tumor reduction.

Efficacy of nab-sirolimus in patients with tumors harboring pathogenic inactivating alteration in TSC2

  • An 11% ORR, including 2 PRs with one confirmed and one uPR.
  • Twelve patients had SD, 3 of which were greater than or equal to six months, resulting in a clinical benefit rate of 28%.
  • Responses were seen in one epithelial carcinoma and one sarcoma.

No new safety signals were observed, and no grade-four treatment-related events or deaths occurred.

Eighty patients are enrolled in the PRECISION1 trial, supporting the two-thirds interim analysis expected in Q3 of 2024. The ORR analysis in this cohort will be based on an independent radiological review with at least six months of follow-up for all patients. 

The trial is expected to be completed by the end of 2024, with results anticipated in early 2025.

Price Action: AADI shares are down 56.24% at $2.35 during the premarket session on the last check Friday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EquitiesNewsPenny StocksMarketsMoversBriefspremarket tradingwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!